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baroreflex function in experimental renovascular
hypertension with reduced kidney mass
Rainer U Pliquett1,2*, Sebastian Benkhoff1, Oliver Jung1,3 and Ralf P Brandes1Abstract
Background: Dysregulation of the autonomic nervous system is frequent in subjects with cardiovascular disease.
The contribution of different forms of renovascular hypertension and the mechanisms contributing to autonomic
dysfunction in hypertension are incompletely understood. Here, murine models of renovascular hypertension with
preserved (2-kidneys-1 clip, 2K1C) and reduced (1-kidney-1 clip, 1K1C) kidney mass were studied with regard to
autonomic nervous system regulation (sympathetic tone: power-spectral analysis of systolic blood pressure;
parasympathetic tone: power-spectral analysis of heart rate) and baroreflex sensitivity of heart rate by spontaneous,
concomitant changes of systolic blood pressure and pulse interval. Involvement of the renin-angiotensin system
and the rho-kinase pathway were determined by application of inhibitors.
Results: C57BL6N mice (6 to 11) with reduced kidney mass (1K1C) or with preserved kidney mass (2K1C) developed
a similar degree of hypertension. In comparison to control mice, both models presented with a significantly
increased sympathetic tone and lower baroreflex sensitivity of heart rate. However, only 2K1C animals had a lower
parasympathetic tone, whereas urinary norepinephrine excretion was reduced in the 1K1C model. Rho kinase inhibition
given to a subset of 1K1C and 2K1C animals improved baroreflex sensitivity of heart rate selectively in the 1K1C model.
Rho kinase inhibition had no additional effects on autonomic nervous system in either model of renovascular
hypertension and did not change the blood pressure. Blockade of AT1 receptors (in 2K1C animals) normalized the
sympathetic tone, decreased resting heart rate, improved baroreflex sensitivity of heart rate and parasympathetic tone.
Conclusions: Regardless of residual renal mass, blood pressure and sympathetic tone are increased, whereas baroreflex
sensitivity is depressed in murine models of renovascular hypertension. Reduced norepinephrine excretion and/or
degradation might contribute to sympathoactivation in renovascular hypertension with reduced renal mass (1K1C).
Overall, the study helps to direct research to optimize medical therapy of hypertension.
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Nephrogenic arterial hypertension comprising renovas-
cular and renoparenchymal aetiologies is increasingly
prevalent [1]. Hypertensive patients with chronic kidney
disease (CKD) are three times more likely to die within
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unless otherwise stated.[2]. Regarding renovascular hypertension, revascularization
strategies do not convey any benefit when compared to the
best conservative therapy [3,4]. Angiotensin II-subtype-1
(AT1) receptor blockers [5] or angiotensin-converting en-
zyme (ACE) inhibitors [6] slow the progression of CKD,
yet they are contraindicated in bilateral renal artery sten-
osis or in unilateral renal artery stenosis and (functional)
single kidney situation. Given the constraints inherent to
medical and interventional therapies of renovascular
hypertension, novel therapeutic targets are still needed.
The autonomic nervous system is such a potential tar-
get. Baroreflex function is attenuated in renovascular dis-
ease, regardless of residual kidney mass [7]. On the basisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Pliquett et al. BMC Physiology 2014, 14:4 Page 2 of 12
http://www.biomedcentral.com/1472-6793/14/4of the effect of propranolol and atropine methyl nitrate on
resting heart rate, an elevated sympathetic tone in models
of renovascular hypertension with (1-kidney-one-clip;
1K1C) and without kidney-mass reduction (2-kidneys-
one-clip; 2K1C) was identified [8,9]. Aside from heart-rate
changes, muscle sympathetic nerve activity [10] and func-
tional data like cold-pressor test [11] were not affected by
propranolol. Therefore, additional surrogates of sympa-
thetic tone are needed.
The pathomechanism of sympathoactivation in renovas-
cular hypertension is unclear. In experimental renovascu-
lar hypertension with preserved kidney mass (2K1C), the
renin-angiotensin-aldosterone system (RAAS) is found to
be activated [12], and central nervous system effects of
angiotensin II probably are the driving force of sym-
pathoactivation [13]. In experimental renovascular hyper-
tension with reduced kidney mass (1K1C), however, the
RAAS is suppressed [12], and other sympathoactivating
pathomechanisms must be operative.
The intracellular Rho A/Rho kinase system emerges as
a novel target for the treatment of cardiovascular disease
[14]. Rho A, a small GTPase, has numerous functions
and is involved in cytoskeletal organization. Upon acti-
vation, Rho A interacts with and activates the Rho A-
dependent kinase (ROCK). As a consequence endothelial
nitric oxide synthase mRNA is destabilized and cellular
contraction is initiated by means of calcium-sensitization
[15] which also increases endothelial cell permeability [16].
Established Rho A/ROCK inhibitors are Fasudil but
also statins, 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase inhibitors. Statins inhibit the formation of
geranyl-geranylpyrophosphate, a prerequisite for RhoA
membrane anchoring [14,17]. We have previously shown
that simvastatin lowers sympathetic tone in experimental
chronic heart failure, another condition characterized by
sympathoexcitation [18,19]. Also ROCK inhibition (ROKI)
by Fasudil was shown to improve baroreflex sensitivity in
experimental chronic heart failure when given in to the in-
tracerebroventricular space [20]. This effect was blunted
by intracerebroventricular application of L-NAME, an in-
hibitor of endothelial nitric oxide synthase, suggesting dir-
ect central effects and a contribution of central nitric
oxide in this process. The value of ROCK inhibition for
the treatment of hypertension at large, however, is still
unclear.
In the present study, we hypothesize that sympatho-
activation is more pronounced in renovascular hyper-
tension with preserved (2K1C) versus reduced (1K1C)
kidney mass when using heart-rate independent sur-
rogates of sympathetic tone. Sham surgery animals and
irbesartan (Irb)-treated 2K1C animals were used as con-
trol groups. The AT1-receptor blocker treatment was used
as a positive control for its sympathoinhibitory actions
[21-24]. Secondly, we hypothesize that ROKI enhancesbaroreflex sensitivity of heart rate in models of renovascu-
lar hypertension (1K1C; 2K1C) in analogy to the chronic-
heart failure situation [20].
Methods
Animals
Male C57BL/6 N mice (6–11 per group, age: 10–12
weeks, Charles River, Sulzfeld, Germany) were housed in
individual cages in a separate room under standard con-
ditions (21°C, 12 h dark–light cycle), standard chow and
drinking water ad libitum. Care was provided daily at
the same time, body weight was taken weekly. All animal
procedures and experiments adhered to the APS’s Guid-
ing Principles in the Care and Use of Vertebrate Animals
in Research and Training. During surgeries, inhalational
anaesthesia using a precision vaporizer with isoflurane
(2% initially, 0.8–1% continuously in an oxygen stream of
0.2 l/min), and subcutaneous (SC) fentanyl (0.06 mg/kg)
were used. Following surgeries, pain-relief medication
buprenorphine (0.3 mg/kg SC), and antibiotic prophylaxis
with ampicillin (50 mg/kg SC) were administered. After
observing the animals for 4–6 weeks, mice were sacrificed
(isoflurane anaesthesia, decapitation), and heart weight
(absolute and relative to body weight) was determined.
Ethical approval was obtained from local animal-care
officials and the supervising federal authority (approval
number: V54-19c20/15F28K2154 issued by Regierung-
spräsidium Darmstadt, Hesse, Germany).
Telemetric monitoring
Aortic blood pressure of unrestrained, conscious mice
was monitored by telemetry (telemetry unit: TA11PA-
C10, Data Sciences International, St. Paul, Minnesota,
USA) attached to a femoral-artery catheter. For catheter
placement, a 15 mm skin incision was made, and the left
femoral artery and vein were separated using a non-
serrated fine-tip forceps (Dumont®, Roboz Surgical In-
strument Co. Inc., USA). The left femoral artery was tied
off (PERMA-HAND® silk, Ethicon, USA) caudally of the
superficial epigastric and superficial circumflex iliac ar-
tery. A second tie was placed 10 to 12 mm cranially and
kept under tension to stop perfusion. A 90°-bent 26 gauge
injection needle serving as a catheter introducer was in-
serted into the left common femoral artery right above the
distal tie. The telemetry catheter was inserted and ad-
vanced to the proximal tie. After releasing the proximal
tie temporarily, the catheter was further advanced into the
lower aorta (below the renal artery) and secured by two
knots. After freeing a subcutaneous pouch on the right
flank, the transmitter unit connected to the intra-arterial
catheter was inserted and 0.05 – 0.1 g gentamicin solution
(3 mg/g) was applied before skin suture (4–0 Prolene,
Ethicon, USA). Blood pressure readings were transmitted
to a receiver placed below the mouse cage, digitized with
Table 1 Drug uptake with the drinking water (mg/kg/d)











10.5 ± 2.4 10.9 ± 3.5 ns
Irbesartan 26.8 ± 2.0 NA NA
Statistical analysis was performed between groups.
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workstation in a separate room. Systolic and diastolic
blood pressures, pulse pressure and pulse intervals (de-
fined as consecutive dP/dt) were extracted from aortic
blood pressure waveforms using ART 4.2 Gold software
(Data Sciences International; St. Paul, Minnesota, USA).
One week later, the mice were randomized in a 1:2 fashion
to sham surgery (normal controls) or unilateral renal-
artery stenosis, i.e. the 2K1C model of hypertension
with preserved kidney mass. There, a U-shaped metal
clip (Exidel SA, Switzerland; width: 110 ± 0.07 μm) was
implanted around the right renal artery as reported previ-
ously [12,25]. One week later, every second 2K1C mouse
was subjected to nephrectomy of the non-clipped kidney
yielding the 1K1C model of renovascular hypertension
with reduced kidney mass.
Autonomic nervous system testing
After a two-week recovery period, a one-hour baseline
recording was taken in the morning. Thereafter, intra-
peritoneal injections of atropine-methyl nitrate (ATR,
2 mg/kg in 4 ml/kg saline, Sigma) [26] or metoprolol
(MET, 1 mg/kg in 4 ml/kg saline; Sigma) were performed.
ATR was used to block the parasympathetic component
while MET was used to block the sympathetic component
of the autonomic nervous system. After injection of either
substance, another hour of continuous blood-pressure re-
cording was performed. For each one-hour recording, the
last 30 minutes were used for analysis. Mean heart rate
and blood pressure were determined. In addition, con-
secutive, continuous one-minute series of digitized systolic
blood pressure and pulse-interval data were linearly in-
terpolated with an equidistant sampling interval of 0.05 s
(20 Hz). Power spectral analysis of those systolic blood
pressure and pulse intervals was performed using Fourier
transformation (1024-point series corresponding to a
51.2-s period). Each spectral band obtained was a har-
monic of 20/1024 Hz (0.019 Hz). The power spectral
analysis of blood pressure and pulse intervals yielded
intensities (units: mmHg2 and ms2) for a given spectral
bandwidth. The cumulative intensity of the low-frequency
band (0.15-0.6 Hz) of power spectrum of systolic blood
pressure (LF-SBP) was regarded as a quantitative measure
of sympathetic tone, whereas the cumulative intensity of
the high-frequency band (2.5-5.0 Hz) of power spectrum
of heart rate (HF-HRV) was considered as a quantitative
measure of parasympathetic tone [26,27].
Power spectrum (high-frequency band: 1.0-5 Hz) of
systolic blood pressure (HF-SBP) [28,29] and power spec-
trum (low-frequency band: 0.4-1.5 Hz) of heart rate (LF-
HRV) were provided as supplemental data. With regard to
sympathovagal balance, interpretation of HF-SBP data still
remains inconclusive for the mouse model. However,
in contrast to humans, LF-HRV is considered to be analternative quantitative measure of parasympathetic tone
in mice [30].
In addition, changes in resting heart rate after admin-
istration of metoprolol or atropine were determined. An
overnight recovery was required after injection of either
substance.
Baroreflex sensitivity
Baroreflex sensitivity was determined by the sequence
technique [31] of concomitant changes of systolic blood
pressure and pulse intervals (digitized, linearly inter-
polated) utilizing the Hemolab software (http://www.
haraldstauss.com/HemoLab/HemoLab.php). Concomi-
tant changes of systolic blood pressure (of at least
15 mmHg) and pulse intervals of at least 4 consecu-
tive heart beats were correlated. For individual baro-
reflex curves, a correlation coefficient of at least 0.9
was mandated for analysis. In addition, a time delay
of 0 seconds was chosen for analysis of concomitant
blood-pressure and pulse-interval changes according
to a previous study with murine models [32]. The average
of at least 10 individual baroreflex slopes (linear portion of
systolic blood pressure – pulse-interval relationship; unit:
Δbpm/ΔmmHg) was considered as baroreflex sensitivity.
Urinary catecholamine assay
Mice were placed in metabolic cages (Tecniplast) for 24-
hour urine collection. Urine was collected over 24 hours
in a vial containing 30 μl HCl (0.5 mol/l), stored at −20°C.
For analysis urinary norepinephrine, dopamine and epi-
nephrine were determined by a radioimmunoassay method
(LDN 3-CAT RIA, Labor Diagnostika Nord, Nordhorn,
Germany).
Medical intervention
The AT1 receptor blocker irbesartan (Irb) was dissolved in
water (c = 150 mg/l, projected dose: 30 mg/kg/d) and given
to five 2K1C mice orally ad libitum. Drug uptake was re-
corded by weighing drinking bottles every 48 h. Likewise,
the Rho-kinase inhibitor SAR407899A was given to 2K1C
and 1K1C mice with the drinking water (c = 50 mg/l, pro-
jected dose: 10 mg/kg/d). The actual drug uptake is shown
in Table 1. Experiments were carried out after 7 – 9 days
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2K1C animals without treatment. Irbesartan and the Rho-
kinase inhibitor SAR407899A were kindly provided by
Sanofi-Aventis, Frankfurt/Main, Germany.
Statistics
Results are given as means ± one standard deviation. For
inter-group comparisons with equal variances, one-way
ANOVA/Newman-Keul post-hoc test or one- or two-
tailed student’s t-test were used, where appropriate. If
the normality test failed, nonparametric tests (Kruskal
Wallis test/Dunn’s post-hoc test or – for two-groups -
Mann–Whitney-U or Wilcoxon-matched pairs test)
were used, where appropriate. A p < 0.05 was considered
significant. Asterisks highlight significances (*p < 0.05;
**p < 0.01; ***p < 0.001). Statistical analysis was carried
out with Graphpad (La Jolla, California, USA).
Results
Characteristics of models of renovascular arterial
hypertension (2K1C, 1K1C)
Pulse pressure, systolic and diastolic blood pressure were




































































Figure 1 Systolic and diastolic blood pressures and pulse pressure in
(1K1C, 2K1C); absolute and relative heart weights of Control, 1K1C an
treatment (SAR407899A; average uptake: 10.6 ± 2.3 mg/kg/d).of renovascular hypertension as compared to controls
(Figure 1, upper panel). Treatment with the Rho-kinase
inhibitor SAR407899A did not affect blood pressure (data
not shown). In comparison to controls, 1K1C animals also
exhibited an increase in both absolute and relative heart
weight. This difference in heart weight was not observed
after ROKI (SAR407899A) treatment (Figure 1, lower
panel). As the increase in heart weight indicates left-
ventricular hypertrophy, this finding suggests that ROKI
treatment attenuates 1K1C-associated left-ventricular
hypertrophy.
Heart rate was not different among groups at baseline
or following selective autonomic-nervous-system block-
ade with atropine (ATR) or metoprolol (MET) (Table 2).
However, resting heart rate significantly increased in re-
sponse to ATR in all groups. In the control group, ATR
also increased the diastolic blood pressure. Neither pulse
pressure nor systolic blood pressure were affected by
ATR or MET in any group. To gauge autonomic ner-
vous system effects of an AT1 blockade, Irb treatment
was performed in 2K1C animals. Hemodynamic effects
of Irb included a decrease of both systolic blood pres-
































































controls (Control) and in animals with renovascular hypertension
d 2K1C animals with or without prior Rho-kinase inhibitor (ROKI)
Table 2 Baseline characteristics of renovascular-hypertension models (2-kidney-1-clip, 1-kidney-1-clip), and of normal
controls following sham-surgery
Normal controls 2-kidneys-1-clipmodel of hypertension
1-kidney-1-clip
model of hypertension P
Heart rate (bpm) 455.3 ± 60.8 472.5 ± 54.9 463.6 ± 55.4 ns
Systolic blood pressure - baseline (mmHg) 100.9 ± 5.5 144.8 ± 13.0 152.3 ± 16.6 <0.0001
Diastolic blood pressure - baseline (mmHg) 76.7 ± 4.3 106.4 ± 12.7 109.2 ± 8.7 0.0001
Heart rate – after atropine (bpm) 559.8 ± 58.1 575.9 ± 82.5 604.4 ± 55.4 ns
Systolic blood pressure - after atropine (mmHg) 108.9 ± 6.6 152.7 ± 16.1 151.2 ± 15.3 <0.0001
Diastolic blood pressure - after atropine (mmHg) 85.9 ± 6.0 116.0 ± 11.9 111.2 ± 8.4 <0.0001
Heart rate – after metoprolol (bpm) 463.0 ± 74.0 513.8 ± 67.6 479.3 ± 49.4 ns
Systolic blood pressure - after metoprolol (mmHg) 100.2 ± 10.8 155.1 ± 14.9 151.1 ± 15.3 <0.0001
Diastolic blood pressure - after metoprolol (mmHg) 77.3 ± 9.2 114.1 ± 13.4 111.4 ± 10.5 <0.0001
Statistical analysis was performed among groups.
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models of renovascular hypertension, irrespective of
residual renal mass (2K1C, 1K1C)
In comparison to controls, baroreflex sensitivity of heart
rate was significantly attenuated in both models of reno-
vascular hypertension. Beta-1-adrenergic blockade with
MET did not alter this difference (Figure 3A-B). Following
ATR, baroreflex sensitivity of heart rate was blunted in all
groups. AT1-receptor blockade with Irb restored baroreflex













































Figure 2 Systolic and diastolic blood pressures, pulse pressure and h
animals with preserved kidney mass (2K1C) with and without irbesartElevated sympathetic tone in both models of
renovascular arterial hypertension (2K1C, 1K1C)
In comparison to controls, both models of renovascular
hypertension (2K1C, 1K1C) presented with an eleva-
ted sympathetic nervous system tone as determined by
power spectral analysis of systolic blood pressure. In
2K1C as well as in 1K1C animals, sympathoactivation
persisted after ATR application (Figure 4A-B). In the
2K1C model, sympathetic tone was significantly higher









































eart rate in controls (Control) and in renovascular-hypertension
an (Irb) treatment (Irb uptake: 26.8 ± 2.0 mg/kg/d).
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C D




























































































Figure 3 Baroreflex sensitivity of heart rate in controls (Control), 1K1C, and 2K1C animals (A); in Control, 1K1C, and 2K1C animals
following MET (B); in Control, 1K1C, and 2K1C animals following ATR (C); in Control and in irbesartan (Irb)-treated and untreated 2K1C
animals (D).
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tion (Figure 4C-D).Parasympathetic tone is reduced in the model of
renovascular hypertension with preserved kidney mass
(2K1C)
Parasympathetic tone, as determined by the cumulative
intensity of HF-HRV, was significantly attenuated in both
models of renovascular hypertension. Beta-adrenergic
blockade with MET confirmed the significant attenuation
of parasympathetic tone in 2K1C animals. An AT1-
receptor blockade with Irb prevented the significant
attenuation of parasympathetic tone in comparison to
controls (Figure 5, upper panel).
As an alternative assessment of parasympathetic tone,
LV-HRV was determined (Table 3). Following meto-
prolol, LF-HRV data confirmed the suppression of para-
sympathetic tone in 2K1C animals in comparison to
controls (p < 0.05 in post-hoc test). However, when using
LF-HRV as a surrogate for parasympathetic tone, there
was no significant change in parasympathetic tonefollowing AT1-receptor blockade in 2K1C animals
(Table 4). In addition to the LF-HRV data, HF-SBP data
is provided for all groups in Table 3 and Table 4.
Collectively, renovascular hypertension with pre-
served kidney mass (2K1C) associates with a lower
parasympathetic tone when compared to normal con-
trols, which is reversed, at least partly, by AT1 receptor
blocker treatment.Urinary catecholamines do not reflect sympathoexcitation
in renovascular hypertension
Urinary norepinephrine excretion was significantly re-
duced in renovascular hypertension with reduced kidney
mass (1K1C) when compared to normal controls (Figure 5,
lower panel). In renovascular hypertension with preserved
kidney mass, norepinephrine excretion was not different
when compared to 1K1C animals or normal controls. This
finding contrasts telemetric power spectral data of systolic
blood pressure suggesting a state of sympathoactivation in
both models of hypertension (1K1C, 2K1C), irrespective
of residual kidney mass.
A B
C D


















































































Figure 4 Sympathetic tone (LF-SBP) in controls (Control), 1K1C, and 2K1C animals (A); in Control, 1K1C, and 2K1C animals following
ATR (B); in Control, and in 2K1C animals with and without irbesartan (Irb) treatment at baseline (C) or following ATR (D).
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heart rate in renovascular hypertension with reduced
kidney mass
As demonstrated in Figure 6, baroreflex sensitivity of
heart rate was improved by ROKI treatment in renovascu-
lar hypertension with reduced renal mass (1K1C). In con-
trast, ROKI treatment led to an attenuation of baroreflex
sensitivity of heart rate in renovascular hypertension with
preserved kidney mass (2K1C). These differential treat-
ment effects of SAR407899A did, however, not translate
into alterations of sympathetic or parasympathetic tone
(Figure 6).
Discussion
In this study, power spectral analysis of systolic blood
pressure [26] and urinary catecholamines [33] were de-
termined to gauge sympathetic tone. In addition, vagal
tone was assessed using power spectral analysis of heart
rate [26,30]. Slope data of concomitant, spontaneous
pulse-interval and blood-pressure changes were gathered
to estimate baroreflex function [31].
The results suggest that therapeutic interventions in
renovascular hypertension may depend on residual renal
mass. As shown for Rho-kinase inhibition, a beneficialeffect on baroreflex function only emerged in the 1K1C
model, but not in the 2K1C model of renovascular
hypertension. This finding may potentially be due to the
oxidative stress in the 1K1C model which leads to a
more profound Rho A/ROCK activation [34-36]. In ad-
dition, Rho-Kinase inhibition may increase nitric oxide
availability in hypothalamic centres of baroreflex regula-
tion similar to the heart failure situation [20] which, in
turn, improves baroreflex sensitivity of heart rate. Al-
though baroreflex sensitivity of heart rate improved upon
Rho-kinase inhibition in the 1K1C model of hypertension,
this change did not translate into a reduction of the sym-
pathetic or an increase in parasympathetic tone. This ob-
servation was unexpected given that carotid baroreflex
function and/or baroreflex-dependent central nervous sys-
tem regulations affect both sympathetic and parasympa-
thetic tone [37,38].
In renovascular hypertension with preserved kidney
mass (2K1C model), AT1-receptor blockade improved
baroreflex sensitivity of heart rate. These data are sup-
ported by observations in humans with “essential” hyper-
tension [39]. In addition, in response to AT1 receptor
blockade, sympathetic tone normalized in the 2K1C














































































































Figure 5 Upper panel: parasympathetic tone (HF-HRV) in controls (Control) at baseline and following MET; in addition, parasympathetic
tone (HF-HRV) in Control, and in 2K1C animals with and without irbesartan (Irb) treatment; lower panel: 24-hour urinary excretion of
norepinephrine, epinephrine, and dopamine in Control, 1K1C and 2K1C animals.
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not shown to improve baroreflex sensitivity of heart rate
in the 2K1C model. This difference to the 1K1C model
may be due to lower nitric oxide availability in hypothal-
amic centres of baroreflex regulation in the 2K1C model
of hypertension. Additional studies on the effect of Rho
kinase inhibition are therefore needed to dissect the spe-
cific regulations of autonomic nervous system tone in
different models of renovascular hypertension.
Concerning the parasympathetic tone, different results
have been obtained for the renovascular hypertensionTable 3 Supplemental power spectral data, i.e. cumulative int
(HF-SBP) and of low-frequency band of heart rate (LF-HRV), is
as well as in hypertensive animals (2-kidney-1-clip (2K1C); 1-k
Normal controls
LF-HRV 411.1 ± 170.8
LF-HRV following Metoprolol 328.0 ± 103.3
LF-HRV following Atropine 151.0 ± 111.1
HF-SBP 103208 ± 12697
HF-SBP following Metoprolol 102988 ± 12776
HF-SBP following Atropine 134689 ± 25981
Statistical analysis was performed among groups.models with and without reduced kidney mass (1K1C;
2K1C) as well. 2K1C animals showed a significantly de-
pressed parasympathetic tone which persisted after beta-
adrenergic blockade. As novel findings, AT1-receptor
blockade with Irb significantly increased parasympathetic
tone, decreased resting heart rate, and restored baroreflex
sensitivity of heart rate in renovascular hypertension with
preserved kidney mass (2K1C). Baroreflex and heart-rate
data are in line with published evidence from experimen-
tal renoparenchymal hypertension [41]. Given the tremen-
dous effect of baroreflex activating therapies in refractoryensity of high-frequency band of systolic blood pressure
shown in normal control animals following sham surgery
idney-1-clip (1K1C))
2K1C 1K1C P
282.8 ± 125.2 298.9 ± 133.2 0.15
174.7 ± 105.2 271.1 ± 90.2 < 0.05
90.4 ± 43.7 86.2 ± 68.5 < 0.05
154311 ± 35205 159123 ± 24991 <0.001
148740 ± 28677 165959 ± 31325 <0.001
178285 ± 35102 189734 ± 30970 <0.01
Table 4 Supplemental power spectral data, i.e. cumulative intensity of high-frequency band of systolic blood pressure
(HF-SBP) and of low-frequency band of heart rate (LF-HRV), is shown in normal control animals following sham surgery
and in hypertensive animals (2-kidney-1-clip (2K1C)) with and without irbesartan (Irb) treatment
Normal controls 2K1C 2K1C-Irb P
LF-HRV 411.1 ± 170.8 303.9 ± 128.1 328.0 ± 170.5 0.36
LF-HRV following Metoprolol 328.0 ± 103.3 187.3 ± 120.6 439.1 ± 237.3 0.07
LF-HRV following Atropine 151.0 ± 111.1 96.7 ± 52.0 131.7 ± 83.7 0.36
HF-SBP 103208 ± 12697 157333 ± 36560 134874 ± 35018 <0.01
HF-SBP following Metoprolol 102988 ± 12776 154627 ± 28676 147225 ± 32901 <0.01
HF-SBP following Atropine 134689 ± 25981 182574 ± 42032 165463 ± 59555 0.11
Statistical analysis was performed among groups.
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blockade with regard to baroreflex function deserves fur-
ther attention in studies. In the present study, AT1 block-
ade was not applied to 1K1C animals because of the risk
of kidney failure. Previous ultra-short term studies with
losartan have not shown an improved baroreflex functionRho-Kinase inhibition in Renovascu
LF-SBP (symp




















































































Figure 6 Upper panel: baroreflex sensitivity of heart rate in controls (Co
(ROKI) treatment (SAR407899A uptake: 10.9 ± 3.5 mg/kg/d); lower pane
with or without ROKI treatment (SAR407899A uptake: 10.5 ± 2.4 mg/kgin this volume-dependent model of renovascular hyper-
tension (1K1C) [43].
As another main result, both models of renovascular
arterial hypertension exhibited a state of sympathoacti-
vation as detected by power spectral analysis of blood
pressure. Thus, previous results obtained with selectivelar Hypertension (1K1C; 2K1C)
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http://www.biomedcentral.com/1472-6793/14/4blockade (atropine and propranolol) experiments on
heart rate were confirmed [8,9]. For renovascular hyper-
tension with preserved kidney function (2K1C), a preva-
lent sympathoactivation was also reported in a recent
study using the same methodology in rats as used in the
present study [44]. Interestingly, in that study, baroreflex
depression occurred almost instantaneously upon induc-
tion of Goldblatt hypertension (2K1C). In the present
study, the level of sympathoactivation was similar be-
tween 1K1C and 2K1C animals, despite the different
hormonal cause of hypertension [12] and the different
volume state [45]. Apart from renovascular hypertension,
a state of sympathoactivation was found in patients with
“essential” arterial hypertension [46-49] and in chronic
heart failure. In the latter, effects on the central nervous
system by angiotensin II were postulated [50,51]. For the
1K1C model, the detailed mechanism of sympathoacti-
vation, however, is still unclear. In 1K1C animals, renin
release is known to be similar to normal controls [12].
Therefore, systemic RAAS activation cannot be a cause of
sympathoactivation under this condition. However, the
brain “ouabain” and/or the brain renin-angiotensin system
may become pertinent for sympathoactivation in reno-
vascular hypertension with reduced kidney mass possibly
through a sodium-dependent mechanism [52]. In addi-
tion, kidney mass reduction and renal artery stenosis may
reduce urinary norepinephrine excretion as shown here
(Figure 6). Diminished excretion and/or attenuated cat-
echolamine degradation in the kidney [53-55] may lead to
catecholamine accumulation and, potentially, sympathoac-
tivation. As a limitation of the present study, plasma cate-
cholamines were not determined. Uremic toxins are
unlikely to play a sympathoactivating role in the 1K1C
model because glomerular filtration was shown to be re-
duced by only 30% [56].
Conclusions
As main results, sympathetic tone (with or without vagal
blockade) was found to be increased, whereas baroreflex
sensitivity of heart rate was depressed in models of re-
novascular hypertension, irrespective of residual renal
mass. Differential results relate to parasympathetic tone
(with or without beta 1-adrenergic blockade) that was
depressed in the 2K1C model only. In addition, left ven-
tricular hypertrophy was present in experimental reno-
vascular hypertension with reduced renal mass (1K1C)
only. Renal norepinephrine excretion was reduced in the
1K1C model exclusively. Hypothetically, renal reduced
catecholamine excretion and/or impaired renal catechol-
amine degradation may be considered as mechanisms of
sympathoactivation in the 1K1C model. Finally, Rho-
kinase inhibition improved baroreflex function solely in
experimental renovascular hypertension with reduced
renal mass (1K1C), whereas AT1 blockade improvedbaroreflex sensitivity of heart rate in renovascular hyper-
tension with preserved kidney mass (2K1C). Taken to-
gether, Rho-kinase inhibition might be an additive strategy
to improve survival in renovascular hypertension with re-
duced renal mass, whereas low-dose AT1 blockade might
be a therapeutic choice in all other cases of renovascular
hypertension.
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